Medical staff shows on February 26, 2020 at the IHU Mediterranee Infection Institute in Marseille, packets of a Nivaquine, tablets containing chloroquine and Plaqueril, tablets containing hydroxychloroquine, drugs that has shown signs of effectiveness against coronavirus. - The Mediterranee infection Institute in Marseille based in La Timone Hospital is at the forefront of the prevention against coronavirus in France. (Photo by GERARD JULIEN / AFP)
The World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalised patients with COVID-19 after they failed to reduce mortality, Reuters reported.
“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a statement, referring to large multi-country trials that the agency is leading.
The U.N. agency said that the decision, taken on the recommendation of the trial’s international steering committee, does not affect other studies where the drugs are used for non-hospitalised patients or as a prophylaxis.
Another arm of the WHO-led trial is looking at the potential effect of Gilead’s antiviral drug remdesivir on COVID-19.
Today, May 15, 2024, marks the 76th anniversary of Nakba Day, an occasion by which…
President Kais Saied met on Wednesday May 15, 2024 at Carthage Palace with Kamel Feki,…
President Kais Saied summoned Mounir Ben Rjiba, Secretary of State to the Minister of Foreign…
Reaffirmation of the primacy of the law During a recent meeting with Leïla Jaffel, Minister…
Slovak police charged a 71-year-old suspect Juraj Cintula with attempted premeditated murder of the country's…
The United States Central Command (CENTCOM) announced on Wednesday the temporary pier aimed at helping…
This website uses cookies.